Parsippany, New Jersey, UNITED STATES
PARSIPPANY, N.J., June  15, 2023  (GLOBE NEWSWIRE) -- On June 11, 2023, L'Oréal made a notable appearance at 2023 Shanghai International Carbon Neutrality Expo in Technologies, Products and Achievements (Carbon Neutrality Expo), celebrating its grand opening in Hill 7.1, the "Practical Exploration – Low Carbon Lifestyle" exhibition area. Themed around "The Carbon Journey of a Lipstick," L'Oréal committed to its sustainable development program “L’Oréal for the Future," inviting more partners from the ecosystem to navigate the path towards carbon neutrality. L'Oréal persistently believes that one tree does not make a forest, and the journey to carbon neutrality necessitates fostering diverse collaborations, envisioning the future, and strategizing development together. Given its substantial scale and wide-reaching consumer base, the consumer industry plays an instrumental role in this process. As a pioneer in the beauty industry, L'Oréal aspires to join forces with stakeholders in the consumer industry to propel sustainable consumption. At the opening ceremony, L'Oréal orchestrated a "Partners of Tomorrow" series of activities, working with upstream and downstream industry partners to craft a sustainable future. L'Oréal North Asia, in concert with ten strategic suppliers, launched a "Subtle Carbon, Not Subtle Action" carbon reduction manifesto. This included Cainiao Network, Microsoft (China) Co., Ltd., Bloomage Biotech, etc. These ten strategic suppliers all participated in the CDP and Ecovodis ratings and agreed to join the carbon reduction actions advocated by L'Oréal. L'Oréal aims to champion these organizations in their carbon reduction endeavors by adopting a range of initiatives such as knowledge sharing and providing comprehensive training. In doing so, they intend to augment "L'Oréal for the Future" in its pledge to reduce Scope 3 carbon emissions, as outlined by the Greenhouse Gas Protocol (GHG Protocol). Mr. Fabrice Megarbane, President, North Asia Zone & Chief Executive Officer L'Oréal China, expressed, "Through 'The Carbon Journey of a Lipstick' theme, we aspire to convey the beauty we create as a sustainable beauty of the future. We are committed to pioneering our own sustainable development: From the 'Sharing Beauty with All' commitment proposed in 2013 to the new sustainable development commitment 'L'Oréal for the Future' looking towards 2030, we strive to drive our own transformation, coinciding perfectly with China's dual carbon goals. Besides, we are devoted to collaborating with the entire ecosystem to achieve sustainable development, and to practicing sustainable development for the benefit of every individual. From 'I' to 'We,' L'Oréal ceaselessly surpasses itself, striving not only to create beauty but also to contribute with more people to the forging of a beautiful planet. For the Earth, the change starts now!" Bloomage Biotech is a globally renowned biotechnology and biomaterial company. Upholding the corporate mission "Creative technology for vibrant life," Bloomage Biotech primarily focuses on the development and industrial application of biological actives beneficial to life health such as functional sugars, proteins, peptides, amino acids, nucleosides, and natural active compounds. In 2022, Bloomage Biotech's raw material products were exported to over 70 countries and regions overseas, providing services to over 4,000 enterprises in pharmaceuticals, medical beauty, cosmetics, food, and other sectors. Article Source: L'Oréal China Information Center, "At the Inaugural Carbon Expo, L'Oréal Accomplishes Monumental Feats!" About Bloomage Biotech
In 2000, Bloomage Biotech (formerly Bloomage Freda Biopharm Co., Ltd.) took its first steps as a producer of hyaluronic acid using microbial fermentation. After more than 20 years, Bloomage Biotech has emerged as a leading global biotechnology and biomaterial company specializing in hyaluronic acid industrialization. By unleashing the potential of synthetic biotechnology, Bloomage Biotech is dedicated to improving people’s quality of life by creating healthier experiences. Media contact:

L'Oréal, in Partnership with Cainiao Network, Microsoft (China), Bloomage Biotech, and Other Key Suppliers, Unveils 'Subtle Carbon, Not Subtle Action' Carbon Reduction Manifesto

Consumer Discretionary Author: Zhisheng Wang, Yiran Xing Editor: Yiran Xing Updated 13 mins ago (GMT+8)
  
At present, Bloomage Biotech has established a full industrial chain business system for bioactive materials, from raw materials to medical terminal products, functional skin care products, and functional foods, serving the global pharmaceutical, cosmetics, and food industries. Bloomage Biotechnology Corporation Limited (hereinafter referred to as "Bloomage Biotech", Chinese: 华熙生物), headquartered in Jinan, Shandong Province, recently released its 2022 annual report and 2023 quarterly report. In 2022, the company achieved revenue of CNY 6.36 billion (USD 918.6 million), an increase of 28.53% year-on-year, and net profit attributable to its parent reached CNY 971 million, 12.0% higher than in the previous year. In Q1 2023, the company generated operating revenue of CNY 1.31 billion, up 4.01% over the previous year, and a net profit of 200 million yuan, an increase of 0.37% from the same period last year. Founded in 2000, Bloomage Biotech is a leading global biotechnology and biomaterial company, focusing on the development and industrialization of bioactives that contribute to life and health, such as functional sugars, proteins, peptides and amino acids. At present, the company's business mainly covers bioactive raw materials, medical end products and consumer end products (functional skin care products and functional foods); among which, functional skin care products have become the largest contributor to Bloomage Biotech’s main business revenue segment. In 2022, the company's functional skin care products achieved revenue of CNY 4.61 billion, an increase of 38.80% year-on-year, accounting for 72.45% of the main business revenue and a gross margin of 78.37%. Bloomage Biotech has been engaged in the deployment of a globalization strategy since its inception, and has successfully marketed raw materials on a global scale. The company has established several subsidiaries in various countries and regions, including the United States, France, and Japan. As the world's largest manufacturer of hyaluronic acid, Bloomage Biotechl has obtained CEP certification in the EU and DMF registration in the U.S., consolidating its position in the international market. In 2022, Bloomage Biotech's overseas raw material sales revenue reached CNY 426 million, up 21.24% year-on-year. According to the "Global and China’s Hyaluronic Acid (HA) Industry Market Research Report" released by world-renowned market research institute Frost & Sullivan, in 2022, Bloomage Biotech has a market share of 70% in China and a market share of 44% in the world, ranking first in the world. The major competitors of Bloomage Biotech in the biotechnology industry include Chinese companies such as Imeik (Chinese: 爱美客), Sisram Medical (Chinese: 复锐医疗科技), and Huadong Medicine (Chinese: 华东医药), as well as international players such as AbbVie Inc. from the U.S. and L'Oreal from France. According to Frost & Sullivan, the global hyaluronic acid market of the biotechnology industry will maintain a 12.3% compound annual growth rate (CAGR) in the next five years. Zhao Yan, Chairman and General Manager of Bloomage Biotech, said that in the face of this trend, Bloomage Biotech will increase its investment in R&D, hoping that the company will thrive through ongoing innovation and technology to expand its application and market boundaries, and provide strong momentum for the rapid, sustainable, and healthy development of this industry. In 2022, Bloomage Biotech invested CNY 388 million in R&D, an increase of 36.52% year-on-year. As of press time, Huaxin Bio closed at CNY 95.57 apiece, with a market cap of CNY 46.02 billion. Selected reports

Chinese Biotech Firm Bloomage Biotech's Revenue in Q1 2023 Exceeds CNY 1.3 Bn, Up 4% YoY

Tencent invests in Freda Biotech amid Chinese consumers' obsession with hyaluronic acid
2 hours ago
In early December, Tencent became the second-largest shareholder of hyaluronic acid (HA) giant Freda Biotech. The biotech leader increased its shares publicly by introducing strategic investors. After a subscription of 315-million-yuan shares, Guangxi Tencent Venture Capital, a wholly-owned subsidiary of Tencent, make its shareholding ratio reach 8.04%. HA is a sugar molecule naturally present in the skin, which helps to bind water and collagen, making the skin look plumper, fresher, and more hydrated. Freda Biotech is the first domestic cosmetic technology company focusing on HA and polyglutamic acid. Its business includes research, production, brand marketing, and ODM/OEM of skincare products. Bloomage Biotech, another well-known HA manufacture in China, correlated deeply with Freda Biotech. In 2001, Bloomage International Investments Group invested in "Shandong Freda Biopharm," which altered its name into "Bloomage Freda Biopharm" in 2012. The honeymoon between the two did not last long. In 2018, after a series of alterations in shareholding, the company renamed itself "Freda Biotech," while "Bloomage Biotech" became an indie company. The two giants now do not associate in shareholding, but their strategies, concepts, and product lines remain similar, making each other the most significant competitor. For instance, Freda Biotech owns HA skincare brands RELLET（颐莲）, Dr.Alva（瑷尔博士）, while Bloomage Biotech owns BIOHYALUX（润百颜）, QuadHA（夸迪）. According to Statistics, in 2020, the market size of hyaluronic acid for medical aesthetics amounted to 5.1 billion yuan in China , and it was projected to expand to more than double within the next four years. Along with China's booming medical aesthetics industry, biotech companies like Freda and Bloomage have made more public presence. Components of skincare products have become a significant element in some Chinese consumers' decision-making. They buy skincare products based on skin problems, defining certain ingredients as the problem-solver. Among the practical component crazes, "HA craze" is the most well-known one, as you can find it in many other products besides skincare. Freda owns HA eyewash care brand "Newborn Loveye" （心生爱目）； Bloomage added HA in bottled water and branded it as "WHATER" （水肌泉）(water+HA), and its alcohol drink brand "by. Mr. Calm" （休想角落） contains HA and "emotion vitamin" GABA. Look beyond biotech companies; there are a bunch of e-commerce sellers who have widely used HA as a tag in product names, including condoms, shampoo, underwear. The point is to make products persuasive. Tencent's bet on biotech implies its faith in the practical component craze in China. The HA craze might end soon, but the craze on other components still goes on. SHARE

Tencent invests in Freda Biotech amid Chinese consumers' obsession with hyaluronic acid

Bloomage: Injecting Biotechnology into Beauty Care
Bloomage: Injecting Biotechnology into Beauty Care
Listed on the Chinese Star Market in November 2019, Bloomage was trading at CNY 138.01 as of June 24, 2020, over 38% higher than the IPO price of CNY 100. The cosmetics market is booming in China. Image credit: Christin Hume/Unsplash
Associated  Company
► Hyaluronic acid (HA) is a critical ingredient in the booming medical cosmetology in China. ► Bloomage Biotech is the first Chinese company that breaks through in fermentation technology to produce HA, with a positive outlook for future growth. Hyaluronic acid (HA) is not an unfamiliar biotechnological term for many consumers. It has been widely used in many beauty care products available at cosmetic shops. More than this, it is an ingredient with a broad spectrum of applications. This HA is distributed widely across human and animal bodies, especially in connective, epithelial and neural tissues. As a non-replaceable natural biomaterial, this acid has particularly useful physicochemical properties and starts to deplete as the human body ages. So far, it has been applied in the healthcare, cosmetics and functional foods areas. The demand for HA in healthcare, especially in the two segments of ophthalmology and orthopedics, is relatively small but growing at an increasing speed. The other two sectors, cosmetics and foods, almost equally share the rest of the production supply. The year 2018 saw a global production amount of 500 tons of hyaluronic acid. In recent years, the fast development of downstream industries on the application layer has been pushing the market size of HA to grow in parallel. In China, the emergence of the aesthetic medicine industry plays a significant role as an interplay of medical technologies and consumers. Many traditional beauty care big-name giants such as Proya, L’Oréal, Shiseido (a Japanese cosmetics brand) are faced with challenges from the disruptors at the tech and supply end. Once these key ingredient providers, inventors and manufacturers have developed a distribution network to reach out to end consumers, it is only a matter of time before sales-based cosmetics brands lose their business moats. And this is the advantage of a biotech-driven cosmetics company like Bloomage, which reaches out to the end-users through hit products. Business fundamentals analysis
Bloomage engages in providing raw material products for downstream medical institutes, medical end products and functional skin-care products. The raw material business is the largest revenue source for this biotech company and is also the primary segment where the company is anchored. Based on its self-developed microbiological fermentation technology, Bloomage can produce HA in all kinds of high-end specifications and exports the raw materials to over 40 countries, including Japan, the US and EU members. Besides raw materials, Bloomage extends to the application area, providing end products in orthopedics, ophthalmology, plastic surgeries, and skin care. In recent years, the booming aesthetic medicine industry has raised the tide of microplastic operations and beauty care e-commerce, accessing more demand for functional skin-care products. A direct impact on the HA-centered manufacturer and provider is a more balanced business revenue structure. In a look into Bloomage’s clients, the top five names’ weights in the total sales have been decreasing since 2016, from 24.24% to 8.95% in 2019, excluding affiliated companies. On a global scale, the ratio of revenues from outbound areas slightly decreased, to 19.01% in 2019, but the gross margin is relatively stable at somewhere close to 70%. In 2017, Bloomage’s Cayman-based subsidiary spent EUR 14.275 million to acquire Revitacare, a French skin-care products manufacturer company fully. It later transferred 100% equity to Bloomage at a consideration of EUR 17.84 million. Since this deal, Bloomage has officially entered the European beauty care consumer market based on its French research-oriented subsidiary. Medical Cosmetology: The third business pole
A global distribution network reaches out to over 2,000 clients, with some in an over-15-year business relationship. For the fast-growing skin-care products, it utilizes a mixed strategy: online e-commerce selling and offline distribution selling. Even though the skin-care products are not the sexiest in terms of profitability, they do indeed form the segment that has the most substantial potential and is growing fastest. The year of 2019 saw a 118.53% growth in this business standalone compared to 2018. Most of the revenue growth can be attributed to Biohyalux ( 'Run Bai Yan,' 润百颜) – one of its portfolio product brands. The hot product ‘Forbidden City’ lipsticks, co-launched with Forbidden City (a well-known Chinese Qing-dynasty relic museum), attracted a lot of attention and success – these retainable users could be drawn to its other products. Immediately following the Chinese ancient-style lipstick's powerful strike at the market, this company seized the timing to implement more promotion strategies, which meant investing more in the selling expenses. It almost doubled its 2018 marketing and selling expenses in 2019. However, before this, Bloomage accelerated the marketing deployment since an expenditure amount of CNY 107 million in 2016 until a total of CNY 521.37 million in 2019. Along with this, employees' compensation and marketing advertising fees are the costliest because the company has transformed its strategy to boost its medical end products and skin-care products. Valuation growth space
This consumer-oriented biotechnology firm went to China’s SSE Star Market in November 2019. Issued at CNY 47.79 per share, it raised CNY 2.37 billion with a close price of CNY 85.1, 78.07% up on the IPO day. After the recent negative impact of the black swan COVID-19 during the peak time (December 2019 – May 2020), the price was CNY 138.01. The company’s price had soared over 38% in one month, as of June 26. The global HA giant aims to utilize this bankroll to invest in an R&D platform update program and two other production expansion projects for HA raw materials and end products. Following the update of the marketing and selling strategy, R&D capability and production capability are the other two pillars that should follow. Bloomage Biotech primarily engages in areas of biotechnology and cosmetics and its biotechnology-based products, HA raw materials, mainly serves the medical device manufacturers. Thus we need to understand its valuation from biotechnology and cosmetics – both segments. We first prioritize the reference according to Bloomage’s 2019 annual report. It listed four companies as its comparable companies, replacing Shangdong Sinobioway (002581:SZ), Hunan Jingfeng Pharma (000908:SH) and L'Occitane en Provence (0973:HKEX) with Shanghai Jahwa United (600315:SH). Tonghua Dongbao Pharma (600867:SH)

Bloomage: Injecting Biotechnology into Beauty Care

Bloomage Biotech, Chemyunion e Hallstar Beauty são os vencedores da 5a edição do Prêmio ABIHPEC-ITEHPEC
O Prêmio ABIHPEC-ITEHPEC de Inovação, em sua 5ª edição, encerrou o primeiro dia da feira in-cosmetics Latin America, que ocorreu em São Paulo de 18 a 19 de setembro, reconhecendo empresas fabricantes de ingredientes de higiene pessoal, perfumaria e cosméticos que possuem trabalhos com impacto em iniciativas e benefícios ao mercado ou consumidor final. A premiação 2019
Com a presença de Carlos Praes, presidente do Conselho Científico-Tecnológico da ABIHPEC e representante dos especialistas que fizeram parte do comitê de avaliação, foram anunciados os finalistas e vencedores do Prêmio ABIHPEC-ITEHPEC de Inovação 2019, reiterando o papel dos fabricantes no mercado de HPPC. Bloomage Biotech conquistou o troféu ouro
A Bloomage Biotech, empresa chinesa e líder no campo do ácido hialurônico, conquistou o troféu ouro, sendo representada pelo vice-presidente Giuseppe Calloni. “Nossa companhia é baseada em ciência, então todos os nossos produtos desenvolvidos possuem ‘know how’. Nós somos referência de biotecnologia no mundo e investimos muitos recursos nesses 25 anos para desenvolver essas tecnologias. Esperamos que nossas pesquisas ajudem a melhorar a vida de muitas pessoas”, declarou. Reconhecida pela criação e fabricação de ativos inovadores, a Chemyunion ficou com a categoria prata na premiação. Diretor de Marketing e Negócios Internacionais, Sérgio Gonçalves mencionou o esforço e o investimento realizado pela empresa. “Quando a gente se junta para que essa inovação aconteça, e ela chega no mercado e é reconhecida, isso é motivo de muito orgulho do ponto de vista do trabalho, o que nos motiva muito mais”, lembrou. “É um reconhecimento, principalmente, ao time de pesquisa e desenvolvimento que, ano a ano, se esforça e investe pesado no setor de inovação”. A Chemyunion conquistou o troféu prato a 5a edição do Prêmio ABIHPEC-ITEHPEC
A categoria bronze ficou com a Hallstar Beauty. Diretor geral, Leonardo Sabedot lembrou que o resultado é muito importante para a divulgação da marca no país. “É um grande prêmio para nós todos, vindo de uma associação como a ABIHPEC, para a nossa companhia no Brasil, que ainda é jovem, mas também por reconhecer a nossa tecnologia em materiais de alta performance”. Grandes protagonistas no setor de HPPC, através dos trabalhos em inovação e tecnologia, a Galena e a Symrise estavam entre as cinco empresas finalistas, e também tiveram suas ações reconhecidas com um certificado. O presidente executivo da Associação Brasileira da Indústria de Higiene Pessoal, Perfumaria e Cosméticos (ABIHPEC), João Carlos Basilio, celebrou o fato de a premiação reforçar como a inovação e a tecnologia são pilares essenciais na indústria de cuidados pessoais. “Este ano tivemos um resultado surpreendente com crescimento de 64% de inscrições em relação a 2018. A cada edição a qualidade técnica dos trabalhos desenvolvidos pelos fabricantes é reflexo do comprometimento das empresas em apresentar ao mercado iniciativas inovadoras e diferenciadas”. “É um grande orgulho saber que o Prêmio vem ganhando essa repercussão incrível, e que os fabricantes de ingredientes vem apresentando produtos cada vez melhores”, acrescentou a gerente de inovação da entidade, Marina Kobayashi. © 2019 - Brazil Beauty News - www.brazilbeautynews.com
mais recentes

Bloomage Biotech, Chemyunion e Hallstar Beauty são os vencedores da 5a edição do Prêmio ABIHPEC-ITEHPEC

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Bloomage BioTech

Huoyan Investment

Yonghua Capital

Unattributed VC

Bloomage Biotech (688363.SH) specializes in the research and development of fermentation production of hyaluronic acid.

Public

CMC Biologics, fka CMC Biopharmaceuticals, is a global contract process development and manufacturer of monoclonal antibodies, coagulation factors, and other therapeutic proteins. The Company has expertise in delivering custom solutions for the scale-up and cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. CMC Biologics' wide range of integrated services includes cell line development, bioprocess development, formulation, and comprehensive analytical testing. Clients can also benefit from CMC Biologics' proprietary CHEF1 Expression System for mammalian production.

River Vision Development Corp. specializes in the development of teprotumumab, a therapy for an eye condition called Graves' ophthalmopathy.

Dave Madden

President and CEO

Abbott

Incubator/Accelerator

OrgSyn is geared towards providing services to pharmaceutical companies, biotech industries and specialty chemicals by developing processes for Active Pharmaceutical Intermediates (APIs) and providing intermediates and starting material for health care industry.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare Bloomage BioTech vs OrgSyn Laboratory

Customers evaluate the quality of Bloomage BioTech's products using the following success metrics.